Stock Financial Ratios, Dividends, Split History

WLKP / Westlake Chemical Partners LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price22.60
Volume38,500.00
Market Cap ($M)752.74
Enterprise Value ($M)728.96
Book Value ($M)998.75
Book Value / Share30.98
Price / Book0.76
NCAV ($M)-285.14
NCAV / Share-8.84
Price / NCAV-2.56
Income Statement (mra) ($M)
Revenue1,172.98
EBITDA374.41
Net Income353.06
Balance Sheet (mrq) ($M)
Cash & Equivalents27.01
Cash / Share0.84
Assets1,515.28
Liabilities516.53
Quick Ratio5.61
Current Ratio5.75
Share Statistics
Common Shares Outstanding32,237,266
Common Shares Outstanding20
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.35
Return on Assets (ROA)0.23
Return on Equity (ROE)0.38
Identifiers and Descriptors
CUSIP960417103
Central Index Key (CIK)1604665
Industry Groups
SIC 286 - Industrial Organic Chemicals
Related CUSIPS
960417903 960417953

Split History

Stock splits are used by Westlake Chemical Partners LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Industrial Organic Chemicals (286)

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

Related News Stories

Should Value Investors Pick Westlake Chemical (WLKP) Stock?

2018-04-10 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

38 Basic Materials 'Safer' Dividends For March

2018-03-28 seekingalpha
38 of 77 Basic Materials top yield stocks were tagged "safer" for dividends because they showed positive annual-returns, and free cash-flow yields greater than their dividend yields 3/23/18. (61-0)

50 Top Basic Materials Dividend Yields For March

2018-03-27 seekingalpha
Coal, wood, glass, & chemicals topped March's basic materials sector for gains, calculated by broker 1-year targets on 3/23/18. (33-2)

John And Jane - February Dividend Income Tracker - Taxable Account

2018-03-05 seekingalpha
This is the 4th month I have officially tracked dividend income and it was the strongest month yet with a total of $1271.50 of dividends received. (301-1)

Westlake Chemical's (WLK) CEO Albert Chao on Q4 2017 Results - Earnings Call Transcript

2018-02-20 seekingalpha
Westlake Chemical Corporation (NYSE:WLK) Q4 2017 Results Earnings Conference Call February 20, 2018 11:00 AM ET

CUSIP: 960417103